GW4064: Selective Non-Steroidal FXR Agonist for Metabolic and Fibrosis Research

Executive Summary: GW4064 is a potent, selective FXR agonist (EC50: 15 nM in isolated receptor assays; 90 nM in human FXR-transfected cells) and serves as a benchmark tool for studying the FXR signaling pathway and metabolic regulation (APExBIO). It modulates cholesterol and triglyceride levels by activating FXR, impacting bile acid and lipid metabolism (Zhou et al., 2025). GW4064 demonstrates efficacy in animal models of metabolic disorders, but its poor solubility and UV instability restrict clinical development. Primary applications include investigating FXR-related mechanisms, such as the FXR/TLR4 pathway and ferroptosis, in metabolic and fibrotic disease models. This article synthesizes validated claims and provides structured integration strategies for laboratory research.

Biological Rationale

The farnesoid X receptor (FXR) is a ligand-activated nuclear receptor expressed in the liver, intestine, kidney, and adrenal glands. FXR regulates bile acid synthesis, cholesterol homeostasis, and glucose metabolism (Zhou et al., 2025). Dysregulation of FXR signaling is implicated in metabolic syndrome, nonalcoholic fatty liver disease (NAFLD), and fibrotic disorders. FXR activation has been shown to suppress hepatic inflammation, reduce collagen deposition, and modulate the TLR4 pathway. GW4064, a synthetic, non-steroidal FXR agonist, is used to dissect these pathways in cellular and animal models. The compound's high selectivity for FXR over other nuclear receptors enables precise functional studies of FXR-dependent gene networks.

Mechanism of Action of GW4064

GW4064 (3-[(E)-2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]phenyl]ethenyl]benzoic acid; C28H22Cl3NO4; MW: 542.85) binds the ligand-binding domain of FXR and induces a conformational change that promotes coactivator recruitment and target gene transcription (APExBIO). FXR activation by GW4064 leads to:

• Suppression of CYP7A1, reducing bile acid synthesis.
• Decreased hepatic triglyceride and VLDL secretion.
• Inhibition of inflammatory signaling via downregulation of TLR4 expression.
• Enhanced ferroptosis features, contributing to reduced collagen deposition in hepatic stellate cells (Zhou et al., 2025).

GW4064 shows EC50 values of 15 nM (in vitro FXR assay) and 90 nM (in human FXR-expressing cells) under standard buffer and temperature conditions (pH 7.4, 25 °C). The compound is insoluble in water and ethanol but dissolves in DMSO at ≥24.7 mg/mL. Light sensitivity and the stilbene structure limit its long-term stability; storage at -20°C is recommended.

Evidence & Benchmarks

• GW4064 (B1527) lowers serum triglyceride and VLDL secretion in KK-Ay and ob/ob mouse models of metabolic syndrome (APExBIO Product Page).
• GW4064 alleviates NiONP-induced collagen formation in LX-2 cells by activating FXR, suppressing TLR4, and enhancing ferroptosis features (Zhou et al., 2025).
• FXR activation by GW4064 downregulates inflammatory cytokine expression in hepatic stellate cells exposed to fibrogenic stimuli (Zhou et al., 2025).
• In SHP+/+ mice, GW4064 reduces hepatic steatosis and collagen deposition, demonstrating utility in preclinical fibrosis models (Related Article).
• GW4064 enables reproducible FXR activation and downstream gene expression in cell-based reporter assays (pH 7.4, 37°C, 24–48 h exposure) (GW4064: Practical Solutions).

This article extends previous reviews by integrating recent evidence on the FXR/TLR4/ferroptosis axis in fibrosis, clarifying GW4064's molecular effects beyond traditional metabolic endpoints (Translating FXR Signaling).

Applications, Limits & Misconceptions

Applications:

• Molecular dissection of FXR signaling in bile acid, cholesterol, and triglyceride regulation.
• Modeling metabolic syndrome, NAFLD, and hepatic fibrosis in preclinical studies.
• Investigation of the FXR/TLR4 pathway and ferroptosis in cellular models of liver injury (Zhou et al., 2025).
• Tool compound for screening FXR-dependent gene expression.

Common Pitfalls or Misconceptions

• GW4064 is not suitable for therapeutic use due to poor solubility, UV instability, and the presence of a potentially toxic stilbene pharmacophore (APExBIO).
• The compound is ineffective in models lacking functional FXR expression.
• GW4064 does not directly target TLR4; effects on TLR4 are secondary to FXR activation (Zhou et al., 2025).
• Results may be confounded by solvent effects if DMSO concentrations exceed recommended thresholds.
• Long-term stock solutions are unstable; always prepare fresh aliquots for critical assays.

Compared to prior reviews, this article provides an updated, evidence-based boundary for GW4064's research applicability.

Workflow Integration & Parameters

Preparation and Handling: GW4064 is supplied as a solid by APExBIO (SKU B1527). Dissolve in DMSO to a working stock concentration of 24.7 mg/mL. Use within 2–4 weeks; store aliquots at -20°C and protect from light. Avoid repeated freeze-thaw cycles (APExBIO).

Experimental Design: For in vitro studies, apply GW4064 at concentrations of 10–1,000 nM in culture medium (final DMSO ≤0.1%). Incubation periods of 24–48 h are standard for reporter and gene expression assays. For in vivo models, use published dosing regimens (e.g., 30 mg/kg/day by oral gavage in mice), adjusting for solubility and animal health.

Analytical Controls: Include FXR-null or FXR-knockdown controls to confirm pathway specificity. Monitor for off-target effects using transcriptomic or proteomic profiling. Validate compound integrity by HPLC or LC-MS if stored >2 weeks.

This article clarifies the integration of GW4064 into advanced FXR activation workflows, supplementing scenario-based guidance found in GW4064: Practical Solutions for FXR Activation.

Conclusion & Outlook

GW4064 is a validated non-steroidal FXR agonist that drives advances in metabolic and fibrotic disease modeling. Its potent, selective FXR activation facilitates precise studies of lipid homeostasis, bile acid metabolism, and the FXR/TLR4/ferroptosis axis (Zhou et al., 2025). Despite its tool compound limitations, GW4064 remains indispensable for dissecting FXR function and benchmarking new modulators. For current protocols and ordering, see the APExBIO GW4064 product page. This article updates and extends prior discussions by presenting new mechanistic insights and workflow parameters, supporting reproducible and robust FXR research (GW4064: Unlocking FXR Signaling).